{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:30:36Z","timestamp":1747801836688,"version":"3.41.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.therap.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:55:49Z","timestamp":1734454549000},"page":"356-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adalimumab-induced myoclonus: A potential adverse drug reaction?"],"prefix":"10.1016","volume":"80","author":[{"given":"Yasmine Salem","family":"Mahjoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israa","family":"Dahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Zgolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Widd","family":"Kaabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarrah","family":"Kastalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imen","family":"Aouintin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"El Aidli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.12.006_bib0055","article-title":"A case report about adalimumab-induced radiologically isolated syndrome: a significant side effect of tumour necrosis factor inhibitors","volume":"9","author":"Onasanya","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.therap.2024.12.006_bib0060","unstructured":"Humira. Product monograph. Date of revision October 28th, 2024. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=64783769 [Accessed 12 December 2024 (487pp.)]."},{"key":"10.1016\/j.therap.2024.12.006_bib0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11940-016-0404-7","article-title":"Myoclonus: pathophysiology and treatment options","volume":"18","author":"Levy","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.therap.2024.12.006_bib0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.12.006_bib0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/WNF.0000000000000025","article-title":"Flecainide-induced myoclonus","volume":"37","author":"Velasco","year":"2014","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.therap.2024.12.006_bib0080","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MPG.0000000000002654","article-title":"Neurological adverse effects associated with anti-tumor necrosis factor alpha antibodies in pediatric inflammatory bowel diseases","volume":"70","author":"Bertrand","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.therap.2024.12.006_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/14740338.5.1.9","article-title":"Toxicity of infliximab in the course of treatment of Crohn's disease","volume":"5","author":"Bratcher","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2024.12.006_bib0090","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00296-020-04587-4","article-title":"Adalimumab-induced myasthenia gravis: case-based review","volume":"40","author":"Pelechas","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.therap.2024.12.006_bib0095","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00296-021-04822-6","article-title":"Aseptic meningitis in rheumatoid arthritis after anti-TNF administration: a case-based literature review","volume":"41","author":"Y\u0131ld\u0131r\u0131m","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.therap.2024.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00415-018-8900-1","article-title":"Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis","volume":"265","author":"Fionda","year":"2018","journal-title":"J Neurol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:06:54Z","timestamp":1747760814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0040595724002142"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.12.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab-induced myoclonus: A potential adverse drug reaction?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}